AG-URSODIOL TABLET

Negara: Kanada

Bahasa: Inggris

Sumber: Health Canada

Beli Sekarang

Karakteristik produk Karakteristik produk (SPC)
26-09-2023

Bahan aktif:

URSODIOL

Tersedia dari:

ANGITA PHARMA INC.

Kode ATC:

A05AA02

INN (Nama Internasional):

URSODEOXYCHOLIC ACID

Dosis:

500MG

Bentuk farmasi:

TABLET

Komposisi:

URSODIOL 500MG

Rute administrasi :

ORAL

Unit dalam paket:

15G/50G

Jenis Resep:

Prescription

Area terapi:

CHOLELITHOLYTIC AGENTS

Ringkasan produk:

Active ingredient group (AIG) number: 0122789002; AHFS:

Status otorisasi:

APPROVED

Tanggal Otorisasi:

2020-09-23

Karakteristik produk

                                AG-Ursodiol (Ursodiol Tablets)
_ _
Page 1 of 32
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AG-URSODIOL
Ursodiol Tablets
Tablets, 250 mg & 500 mg, Oral
USP
Bile Acid Preparation
Angita Pharma Inc.
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
Date of Initial Authorization:
September 23, 2020
Date of Revision:
September 26, 2023
Submission Control Number: 278847
AG-Ursodiol (Ursodiol Tablets)
_ _
Page 2 of 32
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Gastrointestinal
09/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED .
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
............................................................................................................
4
1.1
Pediatrics
.............................................................................................................................
4
1.2
Geriatrics
.............................................................................................................................
4
2
CONTRAINDICATIONS
...............................................................................................
4
4
DOSAGE AND ADMINISTRATION
...............................................................................
4
4.1
Dosing Considerations
........................................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
................................................................... 5
4.3
Administration
....................................................................................................................
5
4.4
Missed Dose
.....................
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Karakteristik produk Karakteristik produk Prancis 26-09-2023

Peringatan pencarian terkait dengan produk ini